Abstract
Free access to this special issue has been made possible by the financial support of the 1st Annual Treatment as Prevention (TasP) Workshop, held May 4-6, 2011 in Vancouver, British Columbia (BC), Canada. The Workshop was organised and hosted by the BC Centre for Excellence in HIV/AIDS and co-hosted by the International AIDS Society, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the World Health Organization and the National Institute on Drug Abuse. Co-sponsors include the National Institutes of Health Office of AIDS Research, the National Institute of Allergy and Infectious Diseases, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS), the Bill & Melinda Gates Foundation, the Canadian Institutes for Health Research and the Public Health Agency of Canada. Academic partners included the University of British Columbia, Simon Fraser University, Vancouver Coastal Health Authority and Providence Health Care, Vancouver. Industry sponsors included Bristol- Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. Additional Industry supporters included Abbott Laboratories and Biolytical.
Current HIV Research
Title: Acknowledgements and Editorial (Exploring the Role of “Treatment as Prevention”)
Volume: 9 Issue: 6
Author(s): Marianne Harris and Julio S.G. Montaner
Affiliation:
Abstract: Free access to this special issue has been made possible by the financial support of the 1st Annual Treatment as Prevention (TasP) Workshop, held May 4-6, 2011 in Vancouver, British Columbia (BC), Canada. The Workshop was organised and hosted by the BC Centre for Excellence in HIV/AIDS and co-hosted by the International AIDS Society, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the World Health Organization and the National Institute on Drug Abuse. Co-sponsors include the National Institutes of Health Office of AIDS Research, the National Institute of Allergy and Infectious Diseases, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS), the Bill & Melinda Gates Foundation, the Canadian Institutes for Health Research and the Public Health Agency of Canada. Academic partners included the University of British Columbia, Simon Fraser University, Vancouver Coastal Health Authority and Providence Health Care, Vancouver. Industry sponsors included Bristol- Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. Additional Industry supporters included Abbott Laboratories and Biolytical.
Export Options
About this article
Cite this article as:
Harris Marianne and S.G. Montaner Julio, Acknowledgements and Editorial (Exploring the Role of “Treatment as Prevention”), Current HIV Research 2011; 9(6) . https://dx.doi.org/10.2174/157016211798038560
DOI https://dx.doi.org/10.2174/157016211798038560 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Brazilian Genome Sequencing Projects: State of the Art
Recent Patents on DNA & Gene Sequences Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics
Current Drug Safety Frequencies of Single Nucleotide Polymorphisms in Cytochrome P450 Genes (CYP1A2, 2A6, 2B6, 3A4 and 3A5) in a Rwandan Population: Difference to Other African Populations
Current Pharmacogenomics and Personalized Medicine Editorial [Hot Topic: Nucleoside and Nucleotide Therapeutics: Recent Targets in Medicinal Chemistry (Guest Editor: Claire Simons)]
Current Topics in Medicinal Chemistry Invasive Pulmonary Aspergillosis in Acute Leukemia: Current Issues for Pathogenesis, Diagnosis and Treatment
Current Respiratory Medicine Reviews Antiretroviral Therapy in Prevention of HIV and TB: Update on Current Research Efforts
Current HIV Research Bioinformatics and Drug Discovery
Current Topics in Medicinal Chemistry Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Synthesis, admetSAR Predictions, DPPH Radical Scavenging Activity, and Potent Anti-mycobacterial Studies of Hydrazones of Substituted 4-(anilino methyl) benzohydrazides (Part 2)
Current Computer-Aided Drug Design Radiolabeled Iron Oxide Nanoparticles As Dual-Modality SPECT/MRI and PET/MRI Agents
Current Topics in Medicinal Chemistry Induction of Autophagic Cell Death in Apoptosis-resistant Pancreatic Cancer Cells using Benzo[α]phenoxazines Derivatives, 10-methyl-benzo[α]phenoxazine-5-one and benzo[α]phenoxazine-5-one
Anti-Cancer Agents in Medicinal Chemistry C-type Lectin Receptor: Old Friend and New Player
Medicinal Chemistry Overview of Coumarins and its Derivatives: Synthesis and Biological Activity
Letters in Organic Chemistry Isoniazid Induced Metabolic Acidosis and Renal Dysfunction in an Elderly Patient with Chronic Renal Disease
Current Drug Safety Managing the Liabilities Arising from Structural Alerts: A Safe Philosophy for Medicinal Chemists
Current Medicinal Chemistry Macrophage Response to Mycobacterium tuberculosis During HIV Infection Relationships Between Macrophage Activation and Apoptosis.
Current Molecular Medicine Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design Repurposing Drugs to Combat Drug Resistance in Leprosy: A Review of Opportunities
Combinatorial Chemistry & High Throughput Screening Bis(2-aminoimidazolines) and Bisguanidines: Synthetic Approaches, Antiparasitic Activity and DNA Binding Properties
Current Medicinal Chemistry Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued)